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Sclerostin (SOST), an osteocyte-secreted soluble antagonist of the Wnt/β-catenin signalling pathway
 is a potent inhibitor of osteoblastogenesis. Mutations in the SOST gene are associated with loss or decrease of
sclerostin (Sclerosteosis1,2, van Buchem disease3,4),
 is a regulator of the skeletal anabolic action of PTH5-6,
 is a potential treatment for osteoporosis - anti-sclerostin antibodies are being investigated as potential
therapeutic molecules for osteoporosis7-9,
Measurement of circulating sclerostin is therefore of utmost importance for the diagnosis of bone disorders and
therapy effectiveness.
We compared the levels of circulating sclerostin measured using ELISA kits from three different providers: Biomedica
(Vienna, Austria), R&D Systems (Abingdon, UK) and TecoMedical (Sissach, Switzerland).
Introduction
1-Methods
Conclusions
Osteocytes orchestrate bone remodelling by producing  sclerostin 
which inhibits bone formation by osteoblasts
Adapted from Lippuner et al., Swiss Med Wkly. 2012;142:w13624
Norwich Medical School
2-Assay Characteristics
Description of kits used:
BIOMEDICA R&D Systems TECO
ELISA kit cat# BI-20492 DSST00 TE1023HS
Standard range 0- 240 pmol/L 31.3-2000 pg/mL
1.3-88 pmol/L
0-3 ng/mlL
0-132 pmol/L
LOD
LLOQ
3.2 pmol/L
7.5pmol/L
N/A
1.74 pg/mL (7.66 pmol/L)
0.008 ng/ml (0.35 pmol/L)
0.01 ng/ml (0.44 pmol/L)
Sample type Serum /  EDTA or Hep Plasma Serum /  EDTA or Hep Plasma Serum /  EDTA or Hep Plasma
plated coating polyclonal goat anti human SOST 
antibody
monoclonal 
anti human SOST antibody 
Streptavidin
Antibody monoclonal mouse anti human 
SOST antibody – biotin
polyclonal 
anti human SOST
antibody -HRP
polyclonal  anti human SOST Biotin+
monoclonal anti human SOST-HRP
Conjugate streptavidin-HRPO hydrogen peroxide
Substrate TMB TMB TMB
Incubation time /T˚C 21.5hrs / RT 4.5hrs / RT 4.5hrs / RT
Sample volumes (µL) 20 50 25
Samples:
 46 serum randomized samples from healthy volunteers (aged 17-32yrs)
 27 matching EDTA-plasma samples
 Kits were used as per manufacturer’s instructions.
Results are given in pmol/L using a conversion factor of 44 from ng/mL to pmol/L.
Values are given in mean ± SD. Statistical analysis was carried out using SPSS.
 Higher [SOST] obtained with Biomedica (29.5% and 50.6% on average vs TECO and
RnD Systems)
- Biomedica: 39.4 ± 10.3 pmol/L
- R&D Systems: 19.0 ± 4.7 pmol/L
- TECO: 27.2 ± 6.9 pmol/L
 Inter-assay precision:
Six EDTA samples were run in two independent experiments in both assays. A serum
pool was run 8 times on two different plates.
Biomedica: mean at 54 pmol/L (n=16), CV 5%; mean at 154 pmol/L, CV 5%.
Teco: mean at 23.8 pmol/L (n=8), CV 2.8%.
R&D Systems: mean at 9 pmol/L, (n=8), CV 3.9%.
 Intra-assay imprecision: Plasma: as mean of CVs of samples run in duplicates .
Serum pool was run 8 times. See table 1, results expressed as mean CV ± SD.
 Linearity: We assessed the linearity of the assay by diluting samples (n=2) 1:2; 1:4
and 1:8 using the sample diluent provided with the kit. Sample percentage
recovery after dilution was estimated. See table 1.
 Recovery: Spiked recovery (%) was determined by adding a known quantity of
sclerostin to samples with different levels of endogenous sclerostin. See table 1.
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 Higher [SOST] obtained with Biomedica (40% and 78% on average vs TECO and R&D
Systems)
- Biomedica: 36.5 ± 8.3 pmol/L
- R&D Systems: 8.2 ± 3.5 pmol/L
- TECO: 21.9 ± 4.7 pmol/L
Intra-assay (%CV ± SD) Linearity (% ± SD) Recovery (% ± SD)
EDTA SERUM EDTA SERUM EDTA SERUM
Biomedica 7.3 ± 6.2 8.9 ± 11.2 149.5 ± 32.1* 142.7 ± 29.8* 104.0 ± 8.7 93.4 ± 7.1
TECO 2.7 ± 2.5 2.7 ± 2.6 101.8 ± 8.6 98.6 ± 7.0 102.4 ± 10.2 103.4 ±2.1
R&D Systems 7.0 ± 5.4 25.8 ± 5.8 73.26 ± 9.9 125.9 ± 23.9 94.5 ± 2.6 100.7 ± 9.9
* SPSS, different from other kits, p<0.05
y = 0.2682x + 12.367
r² = 0.2104
y = -0.0499x + 9.4032
r² = 0.023
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Both serum and EDTA
samples were from the
same patients.
- Serum [SOST] were 
lower
- R&D systems gave the 
highest difference.
- Low correlation between 
serum and EDTA [SOST] 
when using Biomedica
Mean [SOST] in healthy 
donors as quoted by 
manufacturers
(18.2 pmol/L)
(18.7 pmol/L)
(32.1 pmol/L)
(24.1 pmol/L)
( 7.6 pmol/L)
(26.8 pmol/L)
Bland-Altman plot showing the differences in [SOST] between EDTA and 
Serum samples
Table 1: Intra-assay imprecision, linearity and spiked recovery obtained from the 3 kits tested.
4-Serum samples3-EDTA plasma samples
The variability in values generated from Biomedica, R&D Systems and TECO assays has
raised questions regarding the accuracy and specificity of the assays (e.g. antibodies
used, interference with the matrix or other proteins). To determine the source of
variation between the three kits, specificity experiments are being conducted using
external sources of sclerostin.
Measurement of SOST may be invaluable to understand the mechanism by which
osteocytes regulate bone turnover, however, until the issues mentioned above are
resolved, care should be taken when interpreting the results.
1-Balemans et al., 2001. Hum Mol Gen 10,537-43. 2-Brunkow et al., 2001. Am J Hum Gen 68, 577-89. 3-Balemans et al., 2002. J. Med Gen 
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Fig. 2: Chart of plasma [SOST] obtained with R&D Systems 
and TECO vs Biomedica. 
Fig. 3: Box plot showing distribution of [SOST] 
in plasma obtained with the 3 kits. 
Fig. 4: Chart of serum [SOST] obtained with R&D Systems 
and TECO vs Biomedica. 
Fig. 5: Box plot showing distribution of [SOST] 
in serum obtained with the 3 kits. 
- Serum [SOST] were higher using Biomedica by up to 62pmol/L (p<0.0001)
- EDTA plasma [SOST] higher using Biomedica by up to 32pmol/L (p<0.0001)
- Except for Biomedica, Serum and plasma [SOST] were also significantly different
(p<0.0001 and p<0.03 for R&D and TECO respectively).
The TECO assay demonstrated less variability between duplicates (2.6±2.4 % and
7.3±6.2% and 7.0±5.4% vs Biomedica and R&D respectively). A dilution study showed
that the Biomedica kit over-recovered diluted samples by up to 60%.
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